Ambutung, Narcesa A.
HRN: 23-65-53 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/15/2023
CO-AMOXICLAV 625MG (TAB)
09/15/2023
09/22/2023
ORAL
625mg
TID
Femoral Fracture R; T/C Cerebrql Concussion
Waiting Final Action
Indication: Empiric Type of Infection: Bone & Joint Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes